Schizandrin A Can Inhibit Non‑Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest, Apoptosis and Autophagy

Research suggests that SchA exerted inhibitory effects on NSCLC physiology by inducing cell cycle arrest and apoptosis and partially induces autophagy.

International Journal of Molecular Medicine
Sintilimab Extends PFS for Certain Patients With NSCLC

 After first interim analysis, a statistically significant PFS benefit with sintilimab, bevacizumab biosimilar injection and chemotherapy was shown in the the ORIENT-31 study. 

Second-Line Sotorasib Plus Afatinib for KRAS–Mutant NSCLC

Combination KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with NSCLC and mutated KRAS...

The ASCO Post

Major Pulmonary Resection After Neoadjuvant Chemotherapy or Chemoradiation in Potentially Resectable Stage III Non-Small Cell Lung Carcinoma

Research identifies predictors of postoperative outcome and survival of locally advanced NSCLC resections after neoadjuvant chemotherapy or chemoradiation.

Scientific Reports
The Adaptive Responses in Non-Small Cell Lung Cancer A549 Cell Lines Induced by Low-Dose Ionizing Radiation and the Variations of miRNA Expression

Researchers detected the effects of LDR on apoptosis and cell cycle in lung cancer A549 cell line and screened the relative miRNAs using small RNA sequencing.

Dose Response
CDK14 Expression is Elevated in Patients With Non-Small Cell Lung Cancer and Correlated With Poor Prognosis

Scientists investigate the clinical significance of cyclin-dependent kinase 14 expression in patients with NSCLC.

Journal of International Medical Research
Identification and Validation of Tissue or ctDNA PTPRD Phosphatase Domain Deleterious Mutations as Prognostic and Predictive Biomarkers for Immune Checkpoint Inhibitors in Non-Squamous NSCLC

Scientists report that the tissue and ctDNA PTPRD phosphatase domain mutations functioned as a prognostic biomarker predicting higher ORR and favorable PFS of ICIs.

BMC Medicine
Ensartinib Shows Superior Efficacy to Crizotinib in Advanced ALK-Positive NSCLC

The eXalt3 trial has shown significantly prolonged progression-free survival with ensartinib vs crizotinib in patients with advanced, recurrent, or metastatic ALK-positive NSCLC...

The ASCO Post
Utility of Comprehensive Genomic Profiling in Directing Treatment and Improving Patient Outcomes in Advanced Non-Small Cell Lung Cancer

Researchers provide a re-evaluation on the clinical implications of comprehensive genomic profiling in the current treatment landscape of advanced NSCLC.

BMC Medicine
Poziotinib, a Tyrosine Kinase Inhibitor, for HER2 Exon 20–Mutant NSCLC

Scientists explore poziotinib, an irreversible covalent tyrosine kinase inhibitor thats smaller size and greater flexibility may allow the drug to circumvent steric hindrance...

The ASCO Post
CALR-TLR4 Complex Inhibits Non-Small Cell Lung Cancer Progression by Regulating the Migration and Maturation of Dendritic Cells

Research showed that mCALR expression was positively correlated with DC infiltration in NSCLC tissues.

Frontiers in Oncology
Do Endocrine Adverse Events Predict Longer Progression-Free Survival Among Patients with Non-Small-Cell Lung Cancer Receiving Nivolumab?

The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab.

Development of a Novel ALK Rearrangement Screening Test for NSCLC

This study aims to overcome the obstacles of ALK fusion gene detection by RT-PCR in the context of suboptimal RNA quality and unknown fusion partners of ALK.

Development of a Novel ALK Rearrangement Screening Test for Non–Small-Cell Lung Cancers

A novel RNA-based ALK KD analysis was developed for ALK rearrangement screening in MPE and FFPE specimens of NSCLC.

Sugemalimab Deemed Effective as Consolidation for Stage III Non–Small-Cell Lung Cancer

Consolidation with sugemalimab improves PFS, compared with placebo, in patients with unresectable, stage III NSCLC who have not progressed after CRT, phase 3 results suggest.

Cancer Therapy Advisor
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non–Small-Cell Lung Cancer

The aim of this study was to determine whether the protein CDCA3 might be a biomarker for TKI response in EGFR mutant lung cancer. 

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer

This phase III study investigates the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy for advanced sqNSCLC.

Journal of Clinical Oncology
Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

Study investigators report the final results of a phase I study of osimertinib and dasatinib in TKI-naïve patients with EGFR-mutated NSCLC.

Frontiers in Oncology
Prognostic Model of Long-Term Advanced Stage (IIIB-IV) EGFR Mutated NSCLC Survivors Using Real-Life Data

This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months.

BMC Cancer
Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab in Advanced Non–Small-Cell Lung Cancer

This phase Ib study investigates the HDAC6 inhibitor ACY-241 plus nivolumab in patients with previously treated advanced NSCLC who had not received a prior HDAC or ICI.

Frontiers in Oncology
EGFR Exon 18 Mutations in Advanced Non–Small-Cell Lung Cancer

The aim of this study is to investigate the response of patients with NSCLC harboring EGFR exon 18 mutations to different therapeutic options.

Frontiers in Oncology
MET Amplification as Driver for Some Non–Small-Cell Lung Cancers

A study led by Dr D. Ross Camidge has helped to define MET amplification as a rare but potentially actionable driver for NSCLC.

Oncology Times - Latest Articles
Immunotherapy Creates Balancing Act for Patients With NSCLC

The results of a large, retrospective study of patients who received a form of immunotherapy for NSCLC revealed that patients may get more than one immune-related side effect, and...

Oncology Times - Latest Articles
In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non–Small-Cell Lung Cancer Progression

This study investigates 120 patients with NSCLC to describe the immune-matricellular phenotypes of their TME and their relationship with malignant cells.

Frontiers in Immunology
Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

This study compares clinical outcomes in a cohort of patients with advanced NSCLC with targetable genomic alterations detected using plasma-based ctDNA or tumor-based...

JCO Precision Oncology
Amivantamab for Patients With EGFR Exon 20 Insertion–Mutated NSCLC After Disease Progression on Platinum Therapy

Amivantamab-vmjw given at the selected phase II dose in a phase I trial produces durable responses in patients with EGFR exon 20 insertion–mutated NSCLC whose disease progressed on platinum-based..

The ASCO Post
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in NSCLC Based on CT Images and Clinicopathological Features

The present study compared the predictive performance of pretreatment CT-based radiomics signatures and clinicopathological and CT morphological factors for ligand PD-L1 expression level...

Frontiers in Oncology
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer

This study seeks to answer the question: Could the addition of metformin to CRT, as a concurrent treatment as well as consolidation therapy, improve outcomes in patients without diabetes who have..

JAMA Oncology
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non–Small-Cell Lung Cancer

The aim of this retrospective study is to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.

Frontiers in Oncology
Correlation Between Early Endpoints and Overall Survival in Non–Small-Cell Lung Cancer

Using multiple source databases, study investigators compile a data set including 81 phase II–IV RCTs of patients with non–small-cell lung cancer.

Frontiers in Oncology
Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer

For patients with resectable stage IIIA NSCLC, neoadjuvant CT with cisplatin and docetaxel followed by surgery resulted in a 1-year EFS rate of 48% in the SAKK 16/00 trial and is an accepted...

Journal of Clinical Oncology
Nivolumab in Non–Small-Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

Study investigators aim to examine clinical data and baseline blood test results as potential predictive biomarkers for benefit from nivolumab, in advanced non–small-cell lung cancer patients.

Frontiers in Oncology
Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non–Small-Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination

Study investigators aim to build a nomogram to predict lung cancer specific survival of NSCLC patients with ipsilateral pleural dissemination and to compare the impact of primary tumor resection...

Frontiers in Oncology

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)